Tech Digest

New Study Found Oxaloacetate Could Fight Cancer and Give Calorie Restriction Benefits

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

March 28, 2016

Dear Reader,

I hope you’ll forgive me for being brief this week. Despite the help of an incredibly talented team, I’m a little overwhelmed by the many last minute tasks associated with finishing my book, The Methuselah Effect.

I’ve been researching next-generation antidepressants lately, so my impulse was to write about the statistical connection between slow economic growth and depression… the psychological type, not economic depression. These two types of depression are, however, intimately related.

Bad economic times can cause clinical depression, and vice versa. Psychological depression is a major cause of disability and lost productivity, contributing to slower economic growth. Not only does disability reduce economic growth, it increases healthcare costs.

This is a big problem. The World Health Organization reports that depression is the leading cause of disability worldwide, and in the West, it ranks as the top cause of disease burden—a combined measure of financial costs, morbidity, and mortality.

I don’t think I’ve ever looked at major depressive disorders (MDD) as having such huge macroeconomic impacts. Disease burden, however, is the largest single drag on the economy. Just look at the healthcare business. It’s the largest industrial sector in history, which makes up the lion’s share of government spending.

You wouldn’t know this, unfortunately, if you were only listening to the presidential campaign rhetoric or the media coverage. Most but not all politicians are completely ignorant of that fact that it is possible to create enormous wealth by increasing health spans.

We could accomplish that in large part by lessening the burdens on scientists working on anti-aging medications. But I’ll ignore the inept political establishment and update you on a recent study about one of the most interesting compounds with potentially powerful anti-aging benefits: oxaloacetate (OAA).

Hopefully, OAA will extend your health span and help solve your financial problems. We’ll worry about the rest of the world another day.

More Evidence of Oxaloacetate’s Anti-Aging Benefits

Oxaloacetate is a compound our bodies use to carry out many important functions. That includes the formation of the molecules that form proteins and fatty acids. Most relevant to this article, it plays a critical role in converting food to usable cellular energy (adenosine phosphate or ATP).

It has long been known that the addition of OAA to cells dramatically increased ATP production. It wasn’t, however, practical to supplement with the compound because it quickly degraded at room temperature. Until recently.

This problem was solved by an engineer who figured out how to “heat stabilize” the molecule. Since then, many scientists have begun investigating the use of oxaloacetate for a variety of conditions.

One of the resultant studies published in March 2016 has helped nail down exactly how oxaloacetate affects cellular function—as well as providing more evidence that OAA can help maintain youthful cellular function.

The lead investigator in the study is Russell Swerdlow, MD, Director of the University of Kansas Alzheimer's Disease Center and the KUMC Neurodegenerative Disorders Program.

Swerdlow’s primary work with oxaloacetate has been in Alzheimer’s disease (AD) and Parkinson’s disease. With funding from the Alzheimer’s Association, he studied the effects of OAA on brain metabolism in Alzheimer’s patients. I believe he’s still enrolling patients, but some are already being dosed, so we could see data by the end of this year.

Previous animal studies of OAA in Alzheimer’s mouse models showed significant increases in short-term memory and decreases in beta-amyloids (amino acids found at high levels in the brains of Alzheimer’s patients).

(Here’s a good article from Stanford Medicine about beta-amyloids if you’d like more information.)

Two Takeaways from the Study

1. Oxaloacetate could help fight cancer

This is kind of complicated, but I’ll keep it simple. Your mitochondria, the energy dynamos found in your cells, convert food into usable biological energy (adenosine triphosphate or ATP) in two ways.

One way is to utilize oxygen. It is called oxidative phosphorylation, and most of your ATP comes from this process. But your mitochondria also produce some ATP without oxygen through the process of glycolysis. It’s the process of breaking down glucose to make ATP chemically.

(The Khan Academy has a brilliant tutorial on cellular respiration for those of you who would like to understand these processes more completely.)

Normally, glycolysis is fine, but excess glucose can increase glycolysis in cells. This is called the Crabtree effect, which is temporary. The problem is that cancers suppress oxygen utilization and rely on glycolysis permanently.

 This is called the Warburg effect.

For this reason, scientists have speculated that we could fight cancers by inhibiting the processes that cause both the Crabtree and Warburg effects.

(A 2011 paper from BBA Bioenergetics discussing this possibility is available online at no cost. It is titled, “The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression.”)

The point is relatively simple, however. The Swerdlow paper shows that oxaloacetate suppresses the temporary Crabtree effect in cells, so it may help prevent the Warburg effect and cancer. This is really interesting.

2. The compound could deliver many of the benefits of the calorie restriction diet

Another bit of important data from Swerdlow is that oxaloacetate increases the amount of activated (phosphorylated) SIRT1 protein in the cell. Scientists believe this protein is one of the most important life-extending gene proteins.

Calorie restriction (CR) also activates SIRT1. In fact, the Swerdlow paper seems to show that oxaloacetate’s SIRT1 activation is similar to that seen in calorie restriction.

This may be linked to Swerdlow’s conclusion that oxaloacetate increases both NAD+ levels and the NAD+/NADH ratio. I won’t go again into the NAD stuff here because I’ve written extensively about it in the past.

However, it’s clear that increasing both forms of nicotinamide adenine dinucleotide (NAD) is a good thing. There is evidence that the NAD+/NADH ratio specifically activates SIRT1 production, which may be a primary signal for activating SIRT1.

Another finding reported in the study is that oxaloacetate increases the amount of malate dehydrogenase, an important enzyme, which normally decreases with age. Without it, cells can become senescent. That means they stop dividing normally and just hang around causing problems.

The paper also reports that oxaloacetate doesn’t change a number of important compounds that we don’t want changed. It also increases compounds associated with the healthy production of mitochondria (COX2, PGC1alpha, PGC1beta, and PRC protein).

Mitochondrial dysfunction is one of the main causes of aging. So anything that encourages mitochondrial biogenesis (or the creation of new mitochondria) contributes to health.

Other Anti-Aging Compounds

There are, of course, other important anti-aging compounds out there.

Anatabine, for example, is also known to reduce beta-amyloids in AD animals like oxaloacetate. Unfortunately, this compound is no longer available over the counter, though Rock Creek Pharmaceuticals is taking it through human trials in Europe.

The compound has the potential to treat many age-related diseases, but the first indication, I believe, is psoriasis. Several hundred thousand people took anatabine when it was available, but I am hearing from some former users that OAA provides similar benefits.

The mechanisms of action for these two compounds are very different, however, so I wouldn’t presume that one is a substitute for the other. Hopefully, we will find out that they are synergistic in their anti-aging impacts.

Other potentially revolutionary compounds are coming… some soon. And that once again confirms this fact: we really need bioinformatics solutions to help tailor individual regimens based on genomics and current health markers.

For the record, I have no financial connection to the company that owns the rights to the heat-stabilized version of OAA, which makes it a practical supplement. The company is private so you can’t buy stock in Terra Biological, which markets OAA as benaGene.

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This

We welcome your comments. Please comply with our Community Rules.


There are no comments at this time.

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics